The pool of sRAGE was found unaffected by the presence of diabetes and AGE levels, while it resulted to be elevated in both T2DM and non-diabetics with CHD, suggesting that plasma levels of sRAGE may be associated with plaque vulnerability, in patients with CHD, independently from RAGE levels, according to previous studies [30,31]. This evidence concerns the gene AGER and type 2 diabetes mellitus.